Q-omics provides the consensus-scored SPINK13 profile across patient tissues and cancer cell-line models. SPINK13 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SPINK13 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SPINK13 RNA expression shows 12,411 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where SPINK13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPINK13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPINK13 survival associations across molecular data types. SPINK13 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPINK13 RNA expression–survival associations across cancer types. High SPINK13 expression shows unfavorable associations in KIRP, STAD and THYM, but favorable associations in OV, UCEC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SPINK13 RNA expression.
This table summarizes SPINK13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SPINK13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPINK13 shows lower tumor expression in LUSC and ESCA and higher tumor expression in KIRC, KIRP, LUAD and CHOL. The KIRC box plot shows higher SPINK13 RNA expression in tumor versus normal tissue (log2 FC = +3.005, t-test p < 0.001).
This table shows molecular features associated with SPINK13 in patient tissues and cancer cell lines. In patient samples, SPINK13 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPINK13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and KIDNEY.
